Literature DB >> 18810593

Molecular medicine: predicting and preventing Huntington's disease.

Ferdinando Squitieri1, Milena Cannella, Luigi Frati.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18810593     DOI： 10.1007/s10072-008-0969-3

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  17 in total

1.  Distribution of grey matter atrophy in Huntington's disease patients: a combined ROI-based and voxel-based morphometric study.

Authors:  G Douaud; V Gaura; M-J Ribeiro; F Lethimonnier; R Maroy; C Verny; P Krystkowiak; P Damier; A-C Bachoud-Levi; P Hantraye; P Remy
Journal:  Neuroimage       Date:  2006-07-27       Impact factor: 6.556

2.  Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG.

Authors:  S M Hersch; S Gevorkian; K Marder; C Moskowitz; A Feigin; M Cox; P Como; C Zimmerman; M Lin; L Zhang; A M Ulug; M F Beal; W Matson; M Bogdanov; E Ebbel; A Zaleta; Y Kaneko; B Jenkins; N Hevelone; H Zhang; H Yu; D Schoenfeld; R Ferrante; H D Rosas
Journal:  Neurology       Date:  2006-01-24       Impact factor: 9.910

3.  Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity.

Authors:  H Diana Rosas; David H Salat; Stephanie Y Lee; Alexandra K Zaleta; Vasanth Pappu; Bruce Fischl; Doug Greve; Nathanael Hevelone; Steven M Hersch
Journal:  Brain       Date:  2008-03-12       Impact factor: 13.501

4.  Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease.

Authors:  F Borovecki; L Lovrecic; J Zhou; H Jeong; F Then; H D Rosas; S M Hersch; P Hogarth; B Bouzou; R V Jensen; D Krainc
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-25       Impact factor: 11.205

Review 5.  Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases.

Authors:  Michael T Lin; M Flint Beal
Journal:  Nature       Date:  2006-10-19       Impact factor: 49.962

6.  Presymptomatic tests in Huntington's disease and dominant ataxias.

Authors:  M Cannella; M Simonelli; C D'Alessio; F Pierelli; S Ruggieri; F Squitieri
Journal:  Neurol Sci       Date:  2001-02       Impact factor: 3.307

7.  Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease.

Authors:  Andrea Ciarmiello; Milena Cannella; Secondo Lastoria; Maria Simonelli; Luigi Frati; David C Rubinsztein; Ferdinando Squitieri
Journal:  J Nucl Med       Date:  2006-02       Impact factor: 10.057

8.  Family and molecular data for a fine analysis of age at onset in Huntington disease.

Authors:  F Squitieri; G Sabbadini; P Mandich; C Gellera; E Di Maria; E Bellone; B Castellotti; E Nargi; U de Grazia; M Frontali; A Novelletto
Journal:  Am J Med Genet       Date:  2000-12-11

9.  Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals.

Authors:  J B Penney; A B Young; I Shoulson; S Starosta-Rubenstein; S R Snodgrass; J Sanchez-Ramos; M Ramos-Arroyo; F Gomez; G Penchaszadeh; J Alvir
Journal:  Mov Disord       Date:  1990       Impact factor: 10.338

10.  Atypical movement disorders in the early stages of Huntington's disease: clinical and genetic analysis.

Authors:  F Squitieri; A Berardelli; E Nargi; B Castellotti; C Mariotti; M Cannella; M L Lavitrano; U de Grazia; C Gellera; S Ruggieri
Journal:  Clin Genet       Date:  2000-07       Impact factor: 4.438
View more
  3 in total

1.  Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins.

Authors:  Ferdinando Squitieri; Sara Orobello; Milena Cannella; Tiziana Martino; Pantaleo Romanelli; Giampiero Giovacchini; Luigi Frati; Luigi Mansi; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-11       Impact factor: 9.236

2.  Changes of peripheral TGF-β1 depend on monocytes-derived macrophages in Huntington disease.

Authors:  Alba Di Pardo; Silvia Alberti; Vittorio Maglione; Enrico Amico; Etty P Cortes; Francesca Elifani; Giuseppe Battaglia; Carla L Busceti; Ferdinando Nicoletti; Jean Paul G Vonsattel; Ferdinando Squitieri
Journal:  Mol Brain       Date:  2013-12-13       Impact factor: 4.041

3.  Decreased Metabolism in the Cerebral Cortex in Early-Stage Huntington's Disease: A Possible Biomarker of Disease Progression?

Authors:  Hyeeun Shin; Man Ho Kim; Su Jin Lee; Kyung-Han Lee; Mi-Jung Kim; Ji Sun Kim; Jin Whan Cho
Journal:  J Clin Neurol       Date:  2013-01-03       Impact factor: 3.077
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.